Advances in the understanding and challenges facing the management of first-episode schizophrenia

Beary M Hodgson R Wildgust HJ (2012) A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: clinical and research implications. J Psychopharmacology 26: 52–61.

Cookson J Hodgson R Wildgust HJ (2012) Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. J Psychopharmacology 26: 42–51.

Haddad PM Das A Keyhani S Chaudhry IB (2012) Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head–head comparisons. J Psychopharmacology 26: 15–26.

Kraepelin E (1913) Dementia praecox and paraphrenia. Edinburgh: Livingstone (translated by Barclay RM , 1921)

Leonard BE Schwarz M Myint AM (2012) The metabolic syndrome in schizophrenia: is inflammation a contributing cause? J Psychopharmacology 26: 33–41.

National Institute for Clinical Excellence. Guidance on the Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. London: NICE.

Salimi K Jarskog LF Lieberman JA (2009) Antipsychotic drugs for first episode schizophrenia. CNS Drugs 23: 837–855.

Singh SP (2010) Early intervention in psychosis. Br J Psychiatry 196: 343–345.

Taylor M Cavanagh J Hodgson R Tiihonen J (2012) Examining the effectiveness of antipsychotic medication in first-episode psychosis. J Psychopharmacology 26: 27–32.

Van Haren NE Cahn W Hulshoff Pol PE Kahn RS (2012) The course of brain abnormalities in schizophrenia: can we slow the progression. J Psychopharmacology 26: 8–14.